Guangxi LiuYao Group Co., Ltd (SHA:603368)
China
· Delayed Price · Currency is CNY 17.30
-0.22 (-1.26%)
At close: Mar 9, 2026
Guangxi LiuYao Group Revenue
Guangxi LiuYao Group had revenue of 5.46B CNY in the quarter ending September 30, 2025, with 1.99% growth. This brings the company's revenue in the last twelve months to 20.95B, down -1.14% year-over-year. In the year 2024, Guangxi LiuYao Group had annual revenue of 21.18B with 1.78% growth.
Revenue (ttm)
20.95B
Revenue Growth
-1.14%
P/S Ratio
0.32
Revenue / Employee
3.80M
Employees
5,513
Market Cap
6.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21.18B | 370.55M | 1.78% |
| Dec 31, 2023 | 20.81B | 1.76B | 9.23% |
| Dec 31, 2022 | 19.05B | 1.92B | 11.19% |
| Dec 31, 2021 | 17.13B | 1.47B | 9.36% |
| Dec 31, 2020 | 15.67B | 811.84M | 5.46% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Realcan Pharmaceutical Group | 7.32B |
| C.Q. Pharmaceutical Holding | 83.08B |
| Qingdao Baheal Medical INC. | 7.58B |
| China National Accord Medicines Corporation | 73.04B |
| Shenzhen Glory Medical | 1.20B |
| China Meheco Group | 33.23B |
| Liaoning Cheng Da | 11.12B |
| China National Medicines Corporation | 51.95B |